



Clinical Endocrinology and Diabetes at a Glance

**Aled Rees
Miles Levy
Andrew Lansdown**

WILEY Blackwell

**Clinical
Endocrinology
and Diabetes
at a Glance**

This title is also available as an e-book.
For more details, please see
www.wiley.com/buy/9781119128717
or scan this QR code:





Clinical Endocrinology and Diabetes at a Glance

Aled Rees

Consultant Endocrinologist
School of Medicine
Cardiff University
Cardiff, UK

Miles Levy

Consultant Endocrinologist
University Hospitals of Leicester
Leicester, UK

Andrew Lansdown

Consultant Endocrinologist
University Hospital of Wales
Cardiff, UK

WILEY Blackwell

This edition first published 2017 © 2017 by John Wiley & Sons, Ltd

Registered office: John Wiley & Sons, Ltd, The Atrium, Southern Gate, Chichester, West Sussex, PO19 8SQ, UK

Editorial offices: 9600 Garsington Road, Oxford, OX4 2DQ, UK
The Atrium, Southern Gate, Chichester, West Sussex, PO19 8SQ, UK
111 River Street, Hoboken, NJ 07030-5774, USA

For details of our global editorial offices, for customer services and for information about how to apply for permission to reuse the copyright material in this book please see our website at www.wiley.com/wiley-blackwell

The right of the authors to be identified as the authors of this work has been asserted in accordance with the UK Copyright, Designs and Patents Act 1988.

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, except as permitted by the UK Copyright, Designs and Patents Act 1988, without the prior permission of the publisher.

Designations used by companies to distinguish their products are often claimed as trademarks. All brand names and product names used in this book are trade names, service marks, trademarks or registered trademarks of their respective owners. The publisher is not associated with any product or vendor mentioned in this book. It is sold on the understanding that the publisher is not engaged in rendering professional services. If professional advice or other expert assistance is required, the services of a competent professional should be sought.

The contents of this work are intended to further general scientific research, understanding, and discussion only and are not intended and should not be relied upon as recommending or promoting a specific method, diagnosis, or treatment by health science practitioners for any particular patient. The publisher and the author make no representations or warranties with respect to the accuracy or completeness of the contents of this work and specifically disclaim all warranties, including without limitation any implied warranties of fitness for a particular purpose. In view of ongoing research, equipment modifications, changes in governmental regulations, and the constant flow of information relating to the use of medicines, equipment, and devices, the reader is urged to review and evaluate the information provided in the package insert or instructions for each medicine, equipment, or device for, among other things, any changes in the instructions or indication of usage and for added warnings and precautions. Readers should consult with a specialist where appropriate. The fact that an organization or Website is referred to in this work as a citation and/or a potential source of further information does not mean that the author or the publisher endorses the information the organization or Website may provide or recommendations it may make. Further, readers should be aware that Internet Websites listed in this work may have changed or disappeared between when this work was written and when it is read. No warranty may be created or extended by any promotional statements for this work. Neither the publisher nor the author shall be liable for any damages arising herefrom.

Library of Congress Cataloging-in-Publication Data

Names: Rees, Aled, author. | Levy, Miles, 1971- author. | Lansdown, Andrew, 1980- author.

Title: Clinical endocrinology and diabetes at a glance / Aled Rees, Miles Levy, Andrew Lansdown.

Other titles: At a glance series (Oxford, England)

Description: Chichester, West Sussex, UK ; Hoboken, NJ : John Wiley & Sons Inc., 2017. | Series: At a glance series | Includes index.

Identifiers: LCCN 2016039440 | ISBN 9781119128717 (pbk.) | ISBN 9781119128724 (Adobe PDF) | ISBN 9781119128731 (epub)

Subjects: | MESH: Endocrine System Diseases—diagnosis | Diabetes Mellitus—diagnosis | Handbooks

Classification: LCC RC648 | NLM WK 39 | DDC 616.4/8—dc23 LC record available at <https://lccn.loc.gov/2016039440>

A catalogue record for this book is available from the British Library.

Wiley also publishes its books in a variety of electronic formats. Some content that appears in print may not be available in electronic books.

Cover image: © SHUBHANGI GANESHRAO KENE/Gettyimages

Set in Minion Pro 9.5/11.5 by Aptara

Contents



Preface vii

Part 1

Introduction 1

- 1 Introduction to endocrinology 2

Part 2

Disorders of the hypothalamic–pituitary axis 5

- 2 The hypothalamic–pituitary axis and its assessment 6
- 3 Acromegaly 8
- 4 Cushing's syndrome 10
- 5 Hypopituitarism and non-functioning pituitary adenomas 12
- 6 Prolactinoma and hyperprolactinaemia 14

Part 3

Disorders of thirst and fluid balance 17

- 7 Hypernatraemia and diabetes insipidus 18
- 8 Hyponatraemia and SIADH 20

Part 4

Thyroid disorders 23

- 9 Thyroid function 24
- 10 Hyperthyroidism: clinical presentation and investigation 26
- 11 Hyperthyroidism: management and ophthalmopathy 28
- 12 Hyperthyroidism: special circumstances 30
- 13 Hypothyroidism 32
- 14 Goitre, thyroid nodules and cancer 34

Part 5

Disorders of calcium homeostasis 37

- 15 Physiology of calcium, PTH and vitamin D metabolism 38
- 16 Hypercalcaemia 40
- 17 Hypocalcaemia 42
- 18 Osteoporosis 44

Part 6

Disorders of the adrenal gland 47

- 19 Steroid physiology and biochemical assessment 48
- 20 Adrenal insufficiency 50
- 21 Adrenocortical tumours 52
- 22 Disorders of the adrenal medulla 54

Part 7

Disorders of the reproductive system 57

- 23 Physiology of the reproductive system 58
- 24 Growth, puberty and sexual differentiation 60
- 25 Menstrual disturbance 62
- 26 Hyperandrogenism 64
- 27 Menopause and HRT 66
- 28 Male hypogonadism 68
- 29 Gynaecomastia 70
- 30 Infertility 72

Part 8

Neuroendocrine tumours 75

- 31 Neuroendocrine tumours 76
- 32 Neuroendocrine tumours: management 78
- 33 Inherited endocrine tumour syndromes 80
- 34 Spontaneous hypoglycaemia 82

Part 9

Endocrine emergencies 85

- 35 Adrenal crisis 86
- 36 Pituitary apoplexy 88
- 37 Myxoedema coma 90
- 38 Thyroid storm 92
- 39 Acute hyponatraemia 94
- 40 Severe hypercalcaemia 96
- 41 Acute hypocalcaemia 98


Part 10

Diabetes mellitus 101

- 42 Overview 102
- 43 Diagnosis and monitoring 104
- 44 Classification 106
- 45 Type 1 diabetes: aetiology and clinical presentation 108
- 46 Type 1 diabetes: insulin and other therapies 110
- 47 Type 2 diabetes: aetiology and clinical presentation 112
- 48 Type 2 diabetes: treatment 114
- 49 Macrovascular complications 116
- 50 Microvascular complications 118
- 51 Diabetic foot disease 120
- 52 Diabetic ketoacidosis 122
- 53 Hyperglycaemic hyperosmolar state 124
- 54 Hypoglycaemia 126
- 55 Peri-operative management 128
- 56 Management of acute illness 131
- 57 Insulin infusions 134
- 58 Pregnancy and diabetes 136
- 59 Genetics of diabetes 138
- 60 The multidisciplinary team 140
- 61 Lipid disorders 142
- 62 Appetite and weight 144
- 63 Obesity and anorexia 146

Index 148

Preface



This concise and informative textbook is aimed primarily at medical undergraduates commencing their clinical rotations, and is the first of its kind to be aligned against a nationally endorsed curriculum (developed by the Society for Endocrinology, Diabetes UK and the Association of British Clinical Diabetologists). Feedback from our students has informed our approach to this book, which seeks to progress the reader from a fundamental understanding of the physiological mechanisms underpinning endocrine regulation through to disease processes which disturb this homeostatic balance. In addition to the core material on common endocrine and diabetes presentations, there is an emphasis on key practical skills and provision of clear guidance on peri-operative management, emergency presentations and acute illness. We therefore anticipate that *Clinical Endocrinology and Diabetes at a Glance* will form a helpful and accessible resource for junior doctors involved in the management of patients with diabetes and endocrine disorders. As with other books in the series there is a major emphasis on the use of clear illustrations and tables to complement the text and consolidate learning.

Parts 1 to 9 cover the regulation and assessment of the endocrine system, pituitary disorders, fluid and electrolyte balance, thyroid disease, metabolic bone disorders, adrenal disease, disorders of the reproductive system, neuroendocrine tumours and endocrine emergencies. Part 10 provides a comprehensive overview of all aspects of diabetes, lipid and weight disorders.

Finally, no textbook makes it to publication without the hard work of a number of contributors. We are particularly grateful to Karen Moore for her diligence in keeping our writing endeavours on track, and to Jan East and Kathy Syplwczak for their help in taking us through the production process.

We welcome any feedback, and hope you enjoy reading the book as much as we have enjoyed writing it.

Aled Rees
Miles Levy
Andrew Lansdown
February 2017



Introduction

Part 1


Chapter

1 Introduction to endocrinology 2

1

Introduction to endocrinology

Figure 1.1 Introduction to endocrinology



Abbreviations: 7TM, 7-trans-membrane; ACTH, adrenocorticotrophic hormone; CRH, corticotrophin releasing hormone; cAMP, cyclic adenosine monophosphate; GH, growth hormone; GHRH, growth hormone releasing hormone; GnRH, gonadotropin-releasing hormone; SRIH, somatostatin; TRH, thyrotrophin releasing hormone; TSH, thyroid stimulating hormone; TSH, trophic hormone.

The endocrine system consists of glands, which secrete hormones that circulate and act at distant sites in the body. The key endocrine glands are the pituitary, thyroid, parathyroids, adrenals, pancreas and gonads. Endocrine disease can lead to hypo- or hypersecretion of hormones. Endocrine diseases include tumours, which are commonly benign, autoimmune diseases, enzyme defects and hormone receptor abnormalities.

Synthesis, release and transport

The chemical structure of hormones includes steroids, polypeptides, glycoproteins and amines (Figure 1.1). Hormones are secreted by the hypothalamus at low concentration, acting locally on the anterior pituitary, which in turn secretes trophic hormones to the relevant target gland. Hormones are secreted directly into the circulation either in their final form or as a larger precursor molecule, such as proopiomelanocortin (POMC), which is cleaved to adrenocorticotrophic hormone (ACTH), melanocyte stimulating hormone (MSH) and other smaller peptides. Many hormones are transported in the circulation by binding proteins, but only the free hormone acts on the receptor. Examples of binding proteins are sex hormone binding globulin (SHBG), which binds testosterone, and cortisol binding globulin (CBG), which binds cortisol.

Mechanisms of hormone action

Cell-surface receptors

Peptide hormones act on cell-surface receptors and exert their effect by activating cyclic adenosine monophosphate (cAMP). Most peptide hormones act via G-protein coupled receptors, most commonly a 7-trans-membrane (7TM) receptor (Figure 1.1). Examples of peptide hormones are growth hormone (GH), thyroid stimulating hormone (TSH), prolactin and ACTH.

Intranuclear receptors

Lipid-soluble hormones such as steroids and thyroid hormones pass through the cell membrane and act on intranuclear receptors, causing altered gene transcription (Figure 1.1).

Control and feedback

Hormones are usually controlled by a negative feedback mechanism (Figure 1.1). Using the thyroid axis as an example, the hypothalamus secretes its thyrotrophin releasing hormone (TRH), which travels down the portal tract to act on the anterior pituitary. The pituitary releases its trophic hormone (TSH) into

the circulation, which acts on the target gland, stimulating the production of the relevant hormone (thyroxine). If the target gland hormone is too low, there is loss of negative feedback and a compensatory increase in the pituitary hormone (low T4, high TSH). If the target gland hormone is too high, there is increased negative feedback and suppression of the pituitary hormone (high T4, low TSH). All pituitary hormones are under predominantly stimulatory control by the hypothalamus apart from prolactin, which is under tonic inhibition by dopamine.

Patterns of hormone secretion

Some hormones are produced in a stable pattern with little circadian rhythmicity, for example thyroxine and prolactin. Other hormones have a significant diurnal variation. For example, cortisol is highest in the morning and lowest at midnight. Minor circadian rhythms can be seen with certain hormones such as testosterone, which is slightly higher in the morning than the afternoon. It is important to measure hormones at the appropriate time of day when assessing for deficiency or excess. Female hormones have a monthly cyclical variation and must be interpreted according to the time of the menstrual cycle.

Measurement of hormones

Hormones are usually measured by immunoassay, which uses specific labelled antibodies that give a signal according to the concentration of hormone. Interfering antibodies can affect blood results, so some results are not reflective of the true concentration of hormone. Assay interference should be suspected in any blood result that does not match the clinical picture. Mass spectrometry is a newer technique that provides a more specific measure, and is increasingly being adopted in endocrine laboratories.

Dynamic endocrine tests

When basal investigations are difficult to interpret because of diurnal variation or equivocal results, 24-hour urine collection or dynamic blood tests can be helpful. If hormone deficiency is suspected, a stimulation test is used. This involves administration of a hormone that stimulates the target gland to increase its hormone secretion. Examples are the Synacthen test (to stimulate cortisol in suspected primary adrenal failure) and the insulin tolerance test (to stimulate GH and ACTH in suspected hypopituitarism). If hormone excess is suspected, a suppression test is used. Examples are the dexamethasone suppression test (to suppress cortisol in suspected Cushing's syndrome) and the oral glucose tolerance test (to suppress GH in suspected acromegaly).



Disorders of the hypothalamic–pituitary axis

Part 2

Chapters

- 2** The hypothalamic–pituitary axis and its assessment 06
- 3** Acromegaly 08
- 4** Cushing's syndrome 10
- 5** Hypopituitarism and non-functioning pituitary adenomas 12
- 6** Prolactinoma and hyperprolactinaemia 14


2

The hypothalamic–pituitary axis and its assessment



Table 2.1 Endocrine tests used to assess hormone levels

Pituitary hormone	Pattern of secretion	Basal test	Dynamic test if deficiency suspected	Dynamic test if excess suspected
GH	Pulsatile release	IGF-1 Random GH	Insulin tolerance test Glucagon test GHRH–arginine	Glucose tolerance test
ACTH	Circadian rhythm (peak am; nadir midnight)	09.00 Cortisol (suspected deficiency) Midnight cortisol (suspected excess)	Insulin tolerance test Synacthen test (not in acute situation)	Dexamethasone Suppression test
LH/FSH	Stable in men Cyclical in women	Any time Follicular phase in female (day 1–5 of period)	N/A	N/A
TSH	Stable secretion	Any time	N/A	N/A
Prolactin	Stable secretion	Any time	N/A	N/A


Figure 2.1 Anatomy



MRI of sagittal view



MRI of coronal view



The pituitary gland is the ‘conductor of the endocrine orchestra’, controlling all peripheral glands via trophic hormones. It is approximately the size of a pea and sits in the pituitary fossa at the base of the brain (Figure 2.1). The anterior pituitary is derived embryologically from Rathke’s pouch, derived from primitive gut tissue. The posterior pituitary is derived from a down-growth of primitive brain tissue. The optic chiasm lies superior to the pituitary gland. Lateral is the cavernous sinus, which contains cranial nerves III, IV and Va and the internal carotid artery (Figure 2.1).

Physiology

Hypothalamic releasing and inhibiting factors are transported along the hypophyseal portal tract to the anterior pituitary. There are five pituitary axes: GH, ACTH, gonadotrophins (FSH and LH), TSH and prolactin (Table 2.1).

Growth hormone

GH is secreted in a pulsatile manner with peak pulses during REM sleep. GH acts on the liver to produce IGF-1, which is used as a marker of GH activity. GH exerts its action both by direct effects of GH and via IGF-1. GH causes musculoskeletal growth in children and has an important role in adults. Growth hormone releasing hormone (GHRH) stimulates GH, while somatostatin inhibits it.

ACTH

ACTH has a circadian rhythm, with peak pulses early in the morning and lowest activity at midnight. ACTH stimulates cortisol release, and is itself stimulated by corticotrophin releasing hormone (CRH). Cortisol is the only hormone that inhibits ACTH.

Gonadotrophins (FSH and LH)

FSH leads to ovarian follicle development in women and spermatogenesis in men. In women, LH causes mid-cycle ovulation during the LH surge and formation of the corpus luteum. In men, LH drives testosterone secretion from testicular Leydig cells. Gonadotrophin releasing hormone (GnRH) stimulates LH and FSH release. Testosterone and oestrogen inhibit LH and FSH, while prolactin also has a direct inhibitory effect.

TSH

TSH drives thyroxine release via stimulation of TSH receptors in the thyroid gland. TRH stimulates TSH secretion and is a weak stimulator of prolactin secretion. Thyroxine directly inhibits TSH.

Prolactin

Prolactin causes lactation and inhibits LH and FSH. It is under predominantly negative control by dopamine and weak stimulatory control by TRH. Anything that inhibits dopamine leads to an elevation in prolactin level.

Assessment of the pituitary gland

Pituitary tumours develop as a result of compression of local structures and/or the effects of endocrine hypo- or hypersecretion. Compression of the optic chiasm classically leads to a bi-temporal hemianopia. Assessment of visual fields with a red pin is a mandatory part of the clinical examination

of patients with pituitary tumours. Automated visual field assessment has superseded Goldmann perimetry as the formal way of documenting visual field defects.

Basal tests

Prolactin and TSH do not have major circadian rhythms so can be checked at any time of day. Both free T₄ (fT₄) and TSH should be checked in pituitary disease because TSH is often normal in secondary hypothyroidism. In women, LH and FSH should be measured within the first 5 days of the menstrual cycle (follicular phase). In men, LH, FSH and basal testosterone should be checked at 09.00 in the fasting state. Basal cortisol should be checked at 09.00 to exclude deficiency, although a stimulatory (Synacthen) test is usually needed to confirm this. IGF-1 is a marker of GH activity: low or low-normal levels suggesting GH deficiency; high levels suggesting GH excess.

Dynamic pituitary tests

Dynamic endocrine tests are used to assess hormones that have a pulsatile secretion or circadian rhythm. If an endocrine deficiency is suspected, a stimulation test is used; if endocrine excess is suspected, a suppression test is used (Table 2.1). All endocrine tests should be interpreted in the clinical context.

Synacthen test

This is predominantly used to assess primary adrenal failure, but also to assess pituitary ACTH reserve. After 2 weeks of ACTH deficiency, atrophy of the adrenal cortex leads to an inadequate response to synthetic ACTH (Synacthen). This test should not be used in the acute situation, such as pituitary apoplexy, or immediately post-pituitary surgery.

Insulin tolerance test

The insulin tolerance test (ITT) is the gold standard test of ACTH and GH reserve. Insulin-induced hypoglycaemia (glucose <2.5 mmol/L) causes physiological stress, leading to a rise in ACTH and GH. A normal cortisol response to hypoglycaemia is >550 nmol/L whereas a GH value >3 µg/dL after hypoglycaemia excludes severe GH deficiency in adults. The ITT is contraindicated in patients with ischaemic heart disease and epilepsy.

Other tests of GH reserve

The ITT is the gold standard assessment of GH reserve, but is an invasive and unpleasant test to undergo. Glucagon can be used instead of the ITT, although it is a less robust test of GH reserve; nausea is a common side effect. The GHRH–arginine test has particular use in patients who have had pituitary radiotherapy. Common side effects of this are flushing, nausea and an unpleasant taste in the mouth.

Imaging

Magnetic resonance imaging (MRI) is the imaging modality of choice for the pituitary gland (Figure 2.1). Dedicated pituitary views with injection of contrast highlight the difference between tumour and normal gland. Pituitary tumours >1 cm are termed macro-adenomas, while lesions <1 cm are called micro-adenomas. Computed tomography (CT) may be adequate in patients who are unable to undergo MRI. There is increasing interest in newer imaging modalities, including ¹¹C-methionine positron emission tomography (PET).